skip to main content

Diabetic kidney disease — SCE Endocrinology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateDiabetesDiabetic kidney diseaseSCE Endocrinology

A 63-year-old man with type 2 diabetes, eGFR 58 ml/min/1.73 m2 and ACR 48 mg/mmol is already on maximum tolerated ACE inhibitor and an SGLT2 inhibitor. Potassium is 4.4 mmol/L. What additional treatment should be considered to reduce kidney and cardiovascular risk?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: CFinerenone

Finerenone can be considered in type 2 diabetes with chronic kidney disease and albuminuria despite optimised standard care, subject to potassium and formulary criteria. Spironolactone is not a routine albuminuria drug and has greater hyperkalaemia/endocrine adverse-effect concerns. Albuminuria is a risk marker and treatment target, not merely a finding to observe.

Reference: NICE TA877; NICE NG203